CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

99mtc mip 1404

Small moleculeexperimentalImaging agent

Clinical trial activity

6 trials · 30 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 2010 (NCT01261754)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
99-technetium

Oral

No

Parenteral

No

Topical

No

Also known as

  • 99mtc mip 1404
  • 99mtc mip 1404
  • 99mtc-mip-1404
  • 99mtc-mip-1404
  • 99mtc-mip-1404
  • technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1h-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1h-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
  • technetium 99m mip-1404

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02615067Phase 3Dec 1, 2015Molecular Insight Pharmaceuticals, University of Washington
NCT01667536Phase 2Aug 1, 2012All-Russia Centre for Urgent Care and Radiation Medicine, Bajcsy-Zsilinszky Hospital, Charles University, City Clinical Hospital # 57, City of Hope National Medical Center, Cornell University, Duke University, Government of Russia, Jahn Ferenc South Pest Hospital, Katholieke Universiteit Leuven, Mayo Clinic, Medical University of South Carolina, Molecular Insight Pharmaceuticals, Moscow Oncology Research Institute, Palacky University, Peterfy Sandor Street Hospital, Radboud University, Research Institute of Oncology n.a. Professor N.N. Petrov under the Federal Agency for Healthcare and Social Development, Russian Academy of Medical Sciences, St. Petersburg State Public Medical Institution, Thomas Jefferson University, Thomayer's Hospital, University of Pilsen, University of Rochester, University of Texas at Houston, University of Turin, University of Washington, University of Wisconsin, Vita-Salute University of Milano. Italy, Wroclaw Medical University
NCT01654874Phase 1Jul 1, 2012Cornell University, Molecular Insight Pharmaceuticals
NCT01615406Phase 1Apr 1, 2012Molecular Insight Pharmaceuticals, University of Texas at Houston
NCT01572701Phase 1Jan 1, 2012Cornell University, Molecular Insight Pharmaceuticals
NCT01261754Phase 1Dec 1, 2010Cornell University, Molecular Insight Pharmaceuticals
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Molecular Insight PharmaceuticalsFor profit6632010
Cornell UniversityAcademic/Hospital4022010
University of Texas at HoustonAcademic/Hospital2022012
University of WashingtonAcademic/Hospital2022012
All-Russia Centre for Urgent Care and Radiation MedicineAcademic/Hospital1012012
Bajcsy-Zsilinszky HospitalAcademic/Hospital1012012
Charles UniversityAcademic/Hospital1012012
City Clinical Hospital # 57Academic/Hospital1012012
City of Hope National Medical CenterAcademic/Hospital1012012
Duke UniversityAcademic/Hospital1012012
Government of RussiaGovernment1012012
Jahn Ferenc South Pest HospitalAcademic/Hospital1012012
Katholieke Universiteit LeuvenAcademic/Hospital1012012
Mayo ClinicAcademic/Hospital1012012
Medical University of South CarolinaAcademic/Hospital1012012
Moscow Oncology Research InstituteAcademic/Hospital1012012
Palacky UniversityAcademic/Hospital1012012
Peterfy Sandor Street HospitalAcademic/Hospital1012012
Radboud UniversityAcademic/Hospital1012012
Research Institute of Oncology n.a. Professor N.N. Petrov under the Federal Agency for Healthcare and Social DevelopmentAcademic/Hospital1012012
30 organizations
Page 1 / 2